Clinical Trial Update: Study on the Safety and Efficacy of Donafinib Combined With Anti-PD-1 Antibody as Adjuvant Therapy for HCC Patients [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating donafinib in combination with an anti-PD-1 antibody as adjuvant therapy for hepatocellular carcinoma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Anti-PD-1 antibody
• Donafinib (donafinib)

Snippet

Sponsor: Zhejiang University | Conditions: Hepatocellular Carcinoma | Phase 1 | Status: COMPLETED